Albany Molecular Research SVP Unloads $24,675 in Stock (AMRI)
Albany Molecular Research (NASDAQ:AMRI) SVP Steven R. Hagen sold 1,250 shares of Albany Molecular Research stock on the open market in a transaction that occurred on Thursday, August 28th. The shares were sold at an average price of $19.74, for a total value of $24,675.00. Following the transaction, the senior vice president now directly owns 30,933 shares in the company, valued at approximately $610,617. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Several analysts have recently commented on the stock. Analysts at Zacks downgraded shares of Albany Molecular Research from an “outperform” rating to a “neutral” rating in a research note on Tuesday, August 12th. They now have a $23.70 price target on the stock. Separately, analysts at Morgan Stanley reiterated an “underperform” rating on shares of Albany Molecular Research in a research note on Monday, July 7th. They now have a $15.00 price target on the stock, up previously from $13.00. Finally, analysts at Sterne Agee reiterated an “underperform” rating on shares of Albany Molecular Research in a research note on Monday, July 7th. They now have a $15.00 price target on the stock, up previously from $13.00.
Shares of Albany Molecular Research (NASDAQ:AMRI) traded down 2.47% during mid-day trading on Tuesday, hitting $19.31. The stock had a trading volume of 534,928 shares. Albany Molecular Research has a 1-year low of $9.71 and a 1-year high of $22.30. The stock’s 50-day moving average is $19.72 and its 200-day moving average is $17.89. The company has a market cap of $609.3 million and a P/E ratio of 39.76.
Albany Molecular Research (NASDAQ:AMRI) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $0.22 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.20 by $0.02. The company had revenue of $68.20 million for the quarter, compared to the consensus estimate of $65.64 million. On average, analysts predict that Albany Molecular Research will post $0.91 earnings per share for the current fiscal year.
Albany Molecular Research, Inc (NASDAQ:AMRI) is a contract research and manufacturing company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.